Optimization of the Quinoline and Substituted Benzyl Moieties of a Series of Phenyltetrazole Leukotriene D4 Receptor Antagonists

Article abstract of DOI:10.1021/jm00085a005

This report describes the development of a series of highly potent quinoline-based leukotriene D₄ (LTD₄) receptor antagonists containing an N-benzyl-substituted phenyltetrazole moiety.They were designed to provide both the correct positioning of the acidic function and secondary lipophilic domain required for strong receptor binding.Members of this series possess high activity in blocking LTD₄-induced contractions of isolated guinea pig ileum.Compound 32, LY287192 (2-<<5-<3-<2-(7-chloroquinolin-2-yl)ethenyl>phenyl>-2H-tetrazol-2-yl>methyl>-5-fluorobenzoic acid sodium salt), blocked contraction with a pK_B value of 9.1+/-0.3.Qualitative structure-activity studies have demonstrated specific requirements for the best activity.In particular, ortho substitution of the benzyl group with an acidic function was crucial for maximum potency.In cases similar to 32, where the benzyl group possesses an ortho carboxylate, the N-2-substituted tetrazole isomer showed 100-fold greater activity relative to the corresponding N-1 isomer.This pattern was reversed when the acid was substituted at the para position.The quinoline unit may be replaced by other nitrogen-containing heterocycles.